Literature DB >> 8552190

Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

T Takai1, M Ono, M Hikida, H Ohmori, J V Ravetch.   

Abstract

Despite its widespread distribution on both lymphoid and myeloid cells, the biological role of the low-affinity immunoglobulin-G receptor, Fc gamma RII, is not fully understood. Defects in this receptor or its signalling pathway in B cells result in perturbations in immune-complex-mediated feedback inhibition of antibody production. We now report that Fc gamma RII-deficient animals display elevated immunoglobulin levels in response to both thymus-dependent and thymus-independent antigens. Additionally, the effector arm of the allergic response is perturbed in these mice. Mast cells from Fc gamma RII-/- are highly sensitive to IgG-triggered degranulation, in contrast to their wild-type counterparts. Fc gamma RII-deficient mice demonstrate an enhanced passive cutaneous analphylaxis reaction, the result of a decreased threshold for mast-cell activation by Fc gamma RIII cross-linking. These results demonstrate that Fc gamma RII acts as a general negative regulator of immune-complex-triggered activation in vivo for both the afferent and efferent limbs of the immune response. Exploiting this property offers new therapeutic opportunities for the treatment of allergic and autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8552190     DOI: 10.1038/379346a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  249 in total

1.  Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells.

Authors:  E Muraille; X Pesesse; C Kuntz; C Erneux
Journal:  Biochem J       Date:  1999-09-15       Impact factor: 3.857

Review 2.  Functions of antibodies in the regulation of B cell responses in vivo.

Authors:  B Heyman
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 3.  Isotype-dependent pathogenicity of autoantibodies: analysis in experimental autoimmune hemolytic anemia.

Authors:  S Izui; L Fossati-Jimack; S A da Silveira; T Moll
Journal:  Springer Semin Immunopathol       Date:  2001-12

4.  Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B.

Authors:  T Uehara; M Bléry; D W Kang; C C Chen; L H Ho; G L Gartland; F T Liu; E Vivier; M D Cooper; H Kubagawa
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 5.  Analyzing the roles of mast cells and basophils in host defense and other biological responses.

Authors:  Stephen J Galli; Jochen Wedemeyer; Mindy Tsai
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

Review 6.  B cell inhibitory receptors and autoimmunity.

Authors:  Nicholas R Pritchard; Kenneth G C Smith
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

7.  Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.

Authors:  Shannon K O'Neill; Andrew Getahun; Stephen B Gauld; Kevin T Merrell; Idan Tamir; Mia J Smith; Joseph M Dal Porto; Quan-Zhen Li; John C Cambier
Journal:  Immunity       Date:  2011-11-09       Impact factor: 31.745

Review 8.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

9.  The inhibitory co-receptor, PECAM-1 provides a protective effect in suppression of collagen-induced arthritis.

Authors:  Mae-Xhum Wong; John D Hayball; P Mark Hogarth; Denise E Jackson
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

10.  Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation.

Authors:  Jonathan A Deane; Prapaporn Pisitkun; Rebecca S Barrett; Lionel Feigenbaum; Terrence Town; Jerrold M Ward; Richard A Flavell; Silvia Bolland
Journal:  Immunity       Date:  2007-11-08       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.